TradingKey

關於 Agios Pharmaceuticals Inc 公司

Agios Pharmaceuticals, Inc. 是一家生物製藥公司。該公司專注於爲患有罕見疾病的患者開發和提供變革性療法。該公司爲患有 PK 缺乏症的成年人銷售一流的丙酮酸激酶 (PK) 激活劑，這是首個用於治療衰弱性溶血性貧血的疾病改良療法。其基因定義疾病 (GDD) 產品組合中的主打候選產品 PYRUKYND (Mitapivat) 是野生型和多種突變型丙酮酸激酶 (PK) 酶的激活劑，用於治療溶血性貧血。Mitapivat 是一種口服小分子，是丙酮酸激酶 R (PKR) 酶的強效激活劑。此外，該公司還在正在進行的臨牀試驗中評估 mitapivat 對 α 和 β 地中海貧血和鐮狀細胞病 (SCD) 的治療效果。該公司還在開發 AG-946，一種臨牀階段的 PKR 酶口服激活劑，用於治療溶血性貧血和包括 SCD 在內的其他適應症。

公司簡介

公司代碼AGIO

公司名稱Agios Pharmaceuticals Inc

上市日期Jul 24, 2013

CEOMr. Brian M. Goff

員工數量486

證券類型Ordinary Share

年結日Jul 24

公司地址88 Sidney Street

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02139

電話16176498600

網址https://www.agios.com/

公司代碼AGIO

上市日期Jul 24, 2013

CEOMr. Brian M. Goff

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Brian M. Goff

Chief Executive Officer, Director

111.92K

+21.20%

Dr. Sarah Gheuens, M.D., Ph.D.

Chief Medical Officer, Head - Research and Development

61.27K

+7.52%

Ms. Cecilia Jones

Chief Financial Officer

30.05K

+16.34%

Ms. Tsveta Milanova

Chief Commercial Officer

26.12K

+14.11%

Dr. Maykin Ho, Ph.D.

Independent Director

17.03K

+14.22%

Ms. Cynthia Smith

Independent Director

10.11K

+26.53%

Mr. Jeffrey D. (Jeff) Capello, CPA

Independent Director

6.07K

+207.34%

Mr. Krishnan Viswanadhan

Chief Corporate Development and Strategy Officer

--

Jay Backstrom

Director

--

Mr. Christopher Taylor

Vice President - Investor Relations and Corporate Communications

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Brian M. Goff

Chief Executive Officer, Director

111.92K

+21.20%

Dr. Sarah Gheuens, M.D., Ph.D.

Chief Medical Officer, Head - Research and Development

61.27K

+7.52%

Ms. Cecilia Jones

Chief Financial Officer

30.05K

+16.34%

Ms. Tsveta Milanova

Chief Commercial Officer

26.12K

+14.11%

Dr. Maykin Ho, Ph.D.

Independent Director

17.03K

+14.22%

Ms. Cynthia Smith

Independent Director

10.11K

+26.53%

收入明細

FY2025Q1

FY2024

FY2023

FY2022

FY2020

FY2019

暫無數據

地區USD

名稱

營收

佔比

United States

8.73M

0.00%

業務

地區

暫無數據

股東統計

更新時間: 7月10日週四

持股股東

股東類型

持股股東

佔比

Farallon Capital Management, L.L.C.

9.81%

The Vanguard Group, Inc.

9.63%

BlackRock Institutional Trust Company, N.A.

7.57%

Bellevue Asset Management AG

6.05%

State Street Global Advisors (US)

4.22%

Other

62.73%

持股股東

佔比

Farallon Capital Management, L.L.C.

9.81%

The Vanguard Group, Inc.

9.63%

BlackRock Institutional Trust Company, N.A.

7.57%

Bellevue Asset Management AG

6.05%

State Street Global Advisors (US)

4.22%

Other

62.73%

股東類型

持股股東

佔比

Investment Advisor

49.06%

Hedge Fund

25.91%

Investment Advisor/Hedge Fund

25.62%

Private Equity

2.65%

Research Firm

2.40%

Individual Investor

1.68%

Pension Fund

0.46%

Bank and Trust

0.33%

Sovereign Wealth Fund

0.25%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

463

62.80M

108.44%

-4.88M

2025Q1

483

63.23M

109.19%

-5.15M

2024Q4

462

62.61M

109.28%

-3.00M

2024Q3

454

61.83M

108.70%

-5.23M

2024Q2

446

61.36M

108.10%

-8.04M

2024Q1

418

65.03M

115.74%

-790.05K

2023Q4

400

62.85M

112.46%

-374.07K

2023Q3

410

61.92M

111.10%

-5.01M

2023Q2

431

62.18M

111.88%

-5.52M

2023Q1

447

61.81M

111.31%

-8.35M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Farallon Capital Management, L.L.C.

5.70M

9.84%

+26.00K

+0.46%

Mar 31, 2025

The Vanguard Group, Inc.

5.59M

9.66%

-26.73K

-0.48%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.40M

7.59%

+17.29K

+0.39%

Mar 31, 2025

State Street Global Advisors (US)

2.45M

4.23%

+297.20K

+13.81%

Mar 31, 2025

T. Rowe Price Associates, Inc.

2.25M

3.89%

-129.04K

-5.42%

Mar 31, 2025

Erste Asset Management GmbH

2.23M

3.85%

+220.00K

+10.95%

Mar 31, 2025

Commodore Capital LP

2.19M

3.77%

+2.19M

--

Mar 31, 2025

Armistice Capital LLC

2.05M

3.54%

-216.30K

-9.55%

Mar 31, 2025

Macquarie Investment Management

1.85M

3.2%

+165.55K

+9.83%

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

WisdomTree BioRevolution Fund

1.94%

Virtus LifeSci Biotech Products ETF

1.86%

ALPS Medical Breakthroughs ETF

1.3%

Harbor Human Capital Factor US Small Cap ETF

0.86%

WisdomTree US SmallCap Fund

0.5%

Invesco NASDAQ Future Gen 200 ETF

0.47%

JPMorgan Healthcare Leaders ETF

0.45%

SPDR S&P Biotech ETF

0.42%

JPMorgan Fundamental Data Science Small Core ETF

0.38%

Global X Aging Population ETF

0.36%

WisdomTree BioRevolution Fund

佔比1.94%

Virtus LifeSci Biotech Products ETF

佔比1.86%

ALPS Medical Breakthroughs ETF

佔比1.3%

Harbor Human Capital Factor US Small Cap ETF

佔比0.86%

WisdomTree US SmallCap Fund

佔比0.5%

Invesco NASDAQ Future Gen 200 ETF

佔比0.47%

JPMorgan Healthcare Leaders ETF

佔比0.45%

SPDR S&P Biotech ETF

佔比0.42%

JPMorgan Fundamental Data Science Small Core ETF

佔比0.38%

Global X Aging Population ETF

佔比0.36%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Agios Pharmaceuticals Inc

28.850USD

Agios Pharmaceuticals Inc

28.850

概覽

公司

財務